21 September 2022 | Other

Merck to begin testing lower dose HIV drug after FDA approval

Merck & Co Inc. has announced a start of last-stage trials for its HIV drug, known as islatravir. The event comes months after the U.S. Food and Drug Administration (FDA) suspended the study, citing safety issues.

As the company states, the Health Department agency reconsidered the plan, agreeing to lower the dose of the once-a-day pills to treat patients with HIV.

Back in December 2021, the FDA completely shelved six studies aimed at developing HIV therapies. Concurrently, the regulator suspended 7 projects, noting some patients were experiencing a lower level of immune system cells that help combat infections.

Merck reported resuming clinical trials of isletravir at lower doses, particularly for adults with HIV-1.

Several higher-dose projects using isletravir are also under clinical hold.

Company MarketCheese
Period: 11.07.2025 Expectation: 920 pips
GBPUSD falls as UK GDP unexpectedly shrinks
Today at 10:42 AM 1
Brent sell
Period: 17.07.2025 Expectation: 150 pips
OPEC's gloomy forecast drags Brent crude prices lower
Today at 08:53 AM 7
Period: 17.07.2025 Expectation: 26000 pips
Institutional investor demand could push ETHUSD to 3,000
Yesterday at 10:38 AM 35
Period: 16.07.2025 Expectation: 2000 pips
USDJPY prepares to retest 148 Level
Yesterday at 08:19 AM 38
Period: 16.07.2025 Expectation: 900 pips
NVIDIA shares rise amid global AI infrastructure investments
09 July 2025 66
Period: 15.07.2025 Expectation: 800 pips
Breaking downtrend could push USDCAD to 1.375
09 July 2025 44
Go to forecasts